贝伐珠单抗联合化疗在老年肺癌患者中的应用及安全性Meta分析  

The application and safety Meta-analysis of bevacizumab combined with chemotherapy in elderly patients with lung cancer

作　　者：吴志海[1] 杨楚钦[1] WU Zhi-hai;YANG Chu-qin(Department of oncology,Shenzhen Longgang Central Hospital,Shenzhen 518116,China)

机构地区：[1]深圳市龙岗中心医院肿瘤科,广东深圳518116

出　　处：《中国处方药》2022年第6期10-12,共3页Journal of China Prescription Drug

摘　　要：目的 评价贝伐珠单抗联合化疗在老年肺癌患者中的应用及安全性情况。方法 计算机检索Cochrane图书馆、PubMed、Ovid Medline、EMbase、中国生物医学文献服务系统(CBM)、中国知网、万方、维普及PubMed、EMbase中贝伐珠单抗联合化疗在老年肺癌患者中的应用及安全性的有关文献,检索时间从建库至2021年10月。将检索最终获得的文献进行归纳、整理,完成摘要的阅读,核对文献的数量、质量并进行验证,采用Revman 5.0软件进行统计分析。结果 初步获得文献121篇,最终纳入文献7篇;7篇符合要求的文献中均涉及临床治疗效果,采用固定效应模型分析,结果可得:贝伐珠单抗联合化疗用于老年肺癌患者中能获得较高的有效率(OR=3.75,95%CI2.84~4.95,P <0.000 01);7篇符合要求的文献中5篇涉及药物安全性,文献间异质性较小(I2=0%,P=0.99);采用固定效应模型分析,结果看出,贝伐珠单抗联合化疗用于老年肺癌患者中安全性较高(OR=2.17,95%CI 1.61~2.92,P <0.000 01)。结论 贝伐珠单抗联合化疗用于老年肺癌患者中,可获得较高的近期疗效,药物安全性较高,考虑到文献的质量与数量,有待高质量研究进一步验证。Objective To evaluate the application and safety of bevacizumab combined with chemotherapy in elderly patients with lung cancer.Methods Computer search of Cochrane Library,PubMed,Ovid Medline,EMbase,China Biomedical Documentation Service System(CBM),CNKI,Wanfang,VIP,Pub Med,EMbase,bevacizumab combined with chemotherapy in elderly patients with lung cancer Relevant documents on the application and safety of the database will be retrieved from the establishment of the database to October 2021.The documents finally obtained from the search are summarized and sorted,the abstract is read,the quantity and quality of the documents are checked and verified,and the Revman5.0 software is used for statistical analysis.Results 121 articles were initially obtained,and 7 articles were finally included;7 articles that met the requirements all involved clinical treatment effects and were analyzed by a fixed-effect model.The results can be obtained:bevacizumab combined with chemotherapy in elderly patients with lung cancer a can be obtained higher therapeutic efficiency(OR = 3.75,95%CI 2.84 ~ 4.95,P < 0.000 01);five of the seven documents that meet the requirements involve drug safety,and the heterogeneity between the documents is small(I2= 0%,P = 0.99);using a fixed-effect model analysis,the results show that bevacizumab combined with chemotherapy is safer in elderly patients with lung cancer(OR = 2.17,95%CI 1.61 ~ 2.92,P < 0.000 01).Conclusion Bevacizumab combined with chemotherapy in elderly patients with lung cancer can obtain high short-term efficacy and high drug safety.Considering the quality and quantity of literature,it needs to be further verified by high-quality research.

关 键 词：贝伐珠单抗 化疗 老年肺癌 近期疗效 安全性 META分析 

分 类 号：R734.2[医药卫生—肿瘤]